HMHaley A. Moss

Haley A. Moss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haley A. Moss has a total of 263 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Who Is Caring for Male Veterans with Breast Cancer? A National Analysis of Surgical Burden Within the Veterans Health Administration

    by Erin M Bayley, Akiko Chiba, Sarah Colonna, Karen M Goldstein, Kara N Maxwell, Megan Shepherd-Banigan, Michael J Kelley, Haley Moss, Leah L Zullig

    Introduction: The epidemiology of breast cancer among men is poorly characterized. As the Veterans Health Administration (VA) serves a disproportionally male population, a larger percentage of breast cancer cases diagnosed and treated in VA are among male patients. However, whether current breast oncology operational infrastructure is prepared to address this need is unclear. Materials and Methods: The VA Breast and Gynecologic Oncology System of Excellence (BGSoE) established a tracking dashboard for all incident breast and gynecologic malignancies in VA in 2021. All breast surgery cases within the VA performed on male Veterans for an indication of cancer in 2023 were reviewed and mapped by the Veterans Integrated Service Network (VISN). Operative cases performed for gynecomastia were excluded. To determine the total affected population, incidence of male breast cancer was calculated using data from the Surveillance, Epidemiology, and End Results (SEER) database. Breast surgeries, reported as a fraction of incident cases, were plotted. The number of active surgeons performing breast surgery in 2023 was garnered from the staff surgeon identified in the BGSoE dashboard. Results: Based upon SEER age-adjusted estimates of breast cancer in men nationally and current Veteran census data, there were estimated to be 188 incident cases of breast cancer among male Veterans in 2023. In comparison, 82 (44%) male Veterans underwent surgery for their breast cancers in VA in 2023. The median age of the cohort was 72 years (interquartile range 58-78). Geographic variability in surgical volume was noted, with the number of surgeries performed in each VISN ranging from 0 to 13 cases. VISNs performed between 0% and 112% of the expected number of cancer operations for male Veterans. All VISNs had at least 1 surgeon performing breast surgery among this population in 2023 (range: 1-15). Conclusions: There is wide variation in incident cases of breast cancer among male Veterans treated in VA. Whether these geographic differences are reflective of differential incidence, discrepancies in access, or availability of breast oncology health services is unclear. Although most patients with breast cancer do present with resectable disease, the proportion of incident cases among male Veterans by our estimates with stage IV disease (not amenable to surgery) cannot be ascertained. Future work will be aimed at characterizing availability of multidisciplinary breast cancer care in VA.

  • Facilitated Cascade Genetic Testing for Relatives of Individuals With BRCA1/2 Pathogenic Variants: A Randomized Controlled Trial

    by Roni Nitecki Wilke, Haley A. Moss, Maria D. Iniesta, Xun Xu, Sarah Linhart, Ravi N. Sharaf, Alexander Melamed, Karen H. Lu, J. Alejandro Rauh-Hain, Melissa K. Frey

    PURPOSE: Despite the potential for substantial public health impact of cascade genetic testing (CGT), few at-risk relatives complete testing. We compared facilitated CGT with standard of care. METHODS: Probands with newly diagnosed BRCA1/2 germline pathogenic variants were cluster-randomized to a facilitated cascade testing intervention or standard care. Random assignment occurred at the proband level and was stratified by personal cancer history, the number of first-degree relatives (FDRs; 1-2 v ≥3), and time since genetic testing (≤6 months v >6-12 months). Adult FDRs without prior testing per self-report were enrolled. The intervention included navigation support and access to genetic testing services; control FDRs received a letter, consistent with standard clinical practice. Free germline genetic testing was available to all FDRs regardless of arm assignment. The primary outcome was completion of genetic testing at 6 months, compared using a two-sided Cochran-Mantel-Haenszel test. RESULTS: Among 151 probands with BRCA1 (52%) or BRCA2 (48%) pathogenic variants, 72% had a prior cancer diagnosis. Probands were randomly assigned, with 142 and 144 FDRs assigned to the intervention and control arms, respectively. At 6 months, genetic testing uptake was significantly higher among FDRs in the intervention group compared with the control group (73.2% [adjusted 95% CI, 64.4 to 82.1] v 50.7% [adjusted 95% CI, 41.0 to 60.4]; P < .001). By 18 months, 90% of intervention FDRs completed genetic testing. Among 206 FDRs who completed testing, 95 (46%) were found to have a pathogenic or likely pathogenic variant; of these, 82 (86%) carried the familial variant. CONCLUSION: In this randomized trial, facilitated CGT significantly increased genetic testing uptake among FDRs of probands with BRCA 1/2 pathogenic variants compared with standard care.

  • Quality of Care in Veterans Affairs Health Care System In-Person and National TeleOncology Service–Delivered Care

    by Leah L. Zullig, Amy S. Jeffreys, Whitney Raska, Gina C. McWhirter, Vida Passero, Daphne R. Friedman, Haley Moss, Maren Olsen, Hollis J. Weidenbacher, Scott E. Sherman, et al.

    PURPOSE: The Veterans Affairs Health Administration (VA) has experience using telehealth (TH) to deliver care to 10 million enrolled Veterans for many clinical care needs. The VA National TeleOncology Service (NTO) was established in 2020 to provide specialized cancer services regardless of geography. We sought to compare quality in TH-delivered cancer services with traditional (TR) in-person VA care. METHODS: Using electronic health record data, we identified patients with an International Classification of Diseases-10 diagnostic code for an incident malignancy from December 2016 to March 2021 at early adopting sites providing both TR and TH care. We classified patients as TH users if they received TH services at least once for their cancer care. We gathered demographic, clinical, and treatment characteristics to calculate 25 Quality Oncology Practice Initiative (QOPI) measures in the symptoms and toxicity management (two), end of life and palliative care (10), and core measure domains (13). We report disease-specific measures, QOPI measures descriptively, and performed chi-square tests to compare TH and TR. RESULTS: We identified 972 patients with lymphoma, prostate, lung, or colorectal cancer. In all, 427 (44%) were TH users. Patients were predominately White (n = 819, 84.3%) men (n = 930, 95.7%). Across 25 QOPI measures, TH users received better (n = 12), worse (n = 10), the same (n = 2), and unevaluable (n = 1) descriptive performance. Appropriate tobacco cessation support within the previous year was higher in TH (85.3% v 76.2%, P = .002). TH and TR rates were similar for the other QOPI measures. CONCLUSION: VA is a leader in TH cancer care because of both its volume and quality. VA-provided TH cancer care quality is similar to or better than that of TR in-person care. NTO specifically, and VA teleoncology broadly, provides another option to Veterans for cancer care.


  • Prevalence of Toxic Exposures Among Women Veterans With Breast or Gynecologic Cancers Receiving Veterans Affairs (VA) Care

    by Megan Shepherd-Banigan, Graham L Cummin, Theodore S Berkowitz, Hollis J Weidenbacher, Haley Moss, Neetu Chawla, Karen M Goldstein, Aditi Hazra, Erin M Bayley, Sarah Colonna, et al.

    Introduction: Toxic exposures have been linked to hormonal disruption and DNA damage, increasing risk for hormone-sensitive cancers, such as breast and gynecologic cancers. However, the effect of toxic exposure on women Veteran cancer risk is unknown, especially for Veterans who served in the recent Middle East conflict because of the latency with which cancer develops. This study assesses the prevalence of toxic exposures among women Veterans with diagnosed breast and gynecologic cancers. Materials and Methods: This descriptive, cross-sectional study examines self-reported toxic exposures among Veterans diagnosed with breast or gynecologic cancers in the Veterans Health Administration and who participated in a clinical care survey with a nurse navigator. Data were obtained from Veteran Health Affairs (VA) electronic medical records and data from the Breast and Gynecologic Oncology System of Excellence (BGSoE) Program Dashboard. Exposure categories include air pollutants, occupational hazards, chemicals, physical agents, and biological risks. We compared demographic, health, and geographic factors between Veterans who reported hazardous exposure versus those who did not and described the characteristics of those hazards. Results: Nearly 50% of women Veterans in the sample reported experiencing a hazardous exposure during military service. Over 80% reported feeling very or somewhat concerned about the exposure. Airborne exposures were the most frequently reported. Conclusions: Women Veterans with breast and/or gynecologic cancer frequently report hazardous exposures during military service, which may impact their actual and perceived cancer risk and subsequent health care utilization. Future research is needed to assess the relationship between perceived/reported and actual hazardous exposures and inform any needed cancer interception.


  • Preferences of BRCA mutation carriers for attributes of risk‐reducing surgical options for breast and ovarian cancer

    by Katherine C. Fitch, Jui‐Chen Yang, Emma S. Ryan, Karen A. Monuszko, Katherine N. Penvose, Sue Friedman, Jennifer K. Plichta, Haley A. Moss, Shelby D. Reed, Laura J. Havrilesky

    Background: Risk‐reducing surgeries are the most effective strategies for cancer prevention in patients with germline pathogenic variants in the BRCA1 / BRCA2 genes; these surgeries are associated with early menopause, loss of childbearing potential, and cosmetic effects. The authors assessed women's preferences for tradeoffs related to risk‐reducing surgical decision making. Methods: Carriers of pathogenic mutations in BRCA1/BRCA2 aged 25–50 years without a personal history of breast, ovarian, peritoneal, or tubal cancer were recruited to complete one of four discrete choice surveys based on their age (younger than 40 years or 40 years and older) and BRCA mutation status (BRCA1 or BRCA2). Participants responded to a series of choices between a do‐nothing strategy and two profiles representing various effects of surgical options on menopause, childbearing potential (those younger than 40 years only), breast appearance, and 10‐year and lifetime risks of breast and ovarian cancer. A conditional logit model was used to quantify participants' choices as a function of surgical options and outcomes. Results: In total, 298 participants completed the survey. Each cohort younger than BRCA1 mutations favored RRSO at age 40 years but with a 56.6% choice probability of delayed RRSO after ages 35–40 years, as recommended by National Comprehensive Cancer Network guidelines. The cohort aged 40 and older with BRCA2 mutations favored RRSO at age 40, 45, or 50 years fairly equally, with a 33.0% choice probability of guideline‐nonconcordant RRSO timing. All cohorts favored mastectomy at younger ages and with reconstruction versus no mastectomy. Conclusions: These findings demonstrate the heterogeneity of preferences and support individualized discussion of treatment goals relating to risk‐reducing surgical planning.


  • The promise and perils of biomarker testing in gynecologic cancers

    by Katherine C. Fitch, Rebecca A. Previs, Haley A. Moss

  • Open Access

    Using Open-Source Large Language Models to Identify Access to Germline Genetic Testing in Veterans With Breast Cancer From Unstructured Text

    by Chunyang Li, Michael Stringer, Vikas Patil, Richard Mcshinsky, Deborah Morreall, Christina Yong, Kelli M. Rasmussen, Zachary Burningham, Suzanne Tamang, Carolyn S. Menendez, et al.

    PURPOSE: The ability of large language models (LLMs) to identify access to germline genetic testing from unstructured text remains unknown. The Department of Veterans Affairs (VA) assessed access in Veterans with breast cancer by implementing and evaluating the performance of open-source, locally deployable LLMs (Llama 3 70B, Llama 3 8B, and Llama 2 70B) in identifying access from clinical/consult notes. METHODS: We identified a cohort of 1,201 Veterans diagnosed with breast cancer between January 1, 2021, and December 31, 2022, who received cancer care within the nationwide VA system and had clinical and/or consult notes available. Notes from a subset of 200 randomly selected patients, reviewed by subject-matter experts to identify access to testing, were split into development and testing sets, and various hyperparameters and prompting approaches were applied. We evaluated LLM performance using accuracy, precision, recall, and F1, with expert consensus on the labeled subset serving as ground truth. We compared LLM-identified access distribution in the entire cohort with expert-identified access in the labeled subset using the chi-squared test. RESULTS: Llama 3 70B achieved an F1 score of 0.912 (95% CI, 0.853 to 0.971), besting Llama 3 8B (F1: 0.811; 95% CI, 0.720 to 0.901) and significantly outperforming Llama 2 70B (F1: 0.644; 95% CI, 0.514 to 0.773; the test set target variable prevalence was 0.72.) We observed no significant difference between the performance of Llama 3 70B and that of the average individual expert reviewer, nor between LLM-identified access distribution across the entire cohort and expert-identified distribution in the labeled subset. CONCLUSION: An open-source, locally deployable LLM effectively and efficiently identified germline genetic testing access from clinical notes. LLMs may enhance care quality and efficiency, while safeguarding sensitive data.


  • Open Access

    Improving Cancer Care for Women Seeking Services in the Veterans Health Administration Through the Breast and Gynecological Oncology System of Excellence

    by Megan Shepherd-Banigan, Leah L Zullig, Theodore S Z Berkowitz, Graham Cummin, Karen M Goldstein, Michael J Kelley, Neetu Chawla, Hollis J Weidenbacher, Aditi Hazra, Ahmad S Halwani, et al.

    Women are the fastest growing population among Veterans and have substantial risk factors that increase their likelihood for developing cancer. To ensure that the Department of Veterans Affairs Veterans Health Administration (VHA) offers the best possible cancer care to women Veterans, it established the Breast and Gynecologic Oncology System of Excellence (BGSoE) in 2021. The BGSoE offers telehealth oncology services and a comprehensive cancer navigation program. Veterans are identified through physician referral or through the BGSoE dashboard which integrates ICD-10 codes and text mining from VA electronic health records to identify eligible Veterans with breast or gynecological cancers. Descriptive statistics, including Veteran demographics and geographical location, were derived from BGSoE dashboard data. From January 1, 2021 to March 15, 2024, the BGSoE identified a total of 7,187 incident cases of breast or gynecological cancer among living Veterans. Most cancers were breast (78%) versus gynecological cancers (22%) and 10% of Veterans with breast cancer were identified as male. The average age at diagnosis was 59 for Veterans with breast cancer and 56 for those Veterans with gynecological cancers. Among Veterans in the BGSoE, 28% identified as Black and 6% identified as Hispanic. As the prevalence of women Veterans requiring cancer-related care continues to rise, it will be essential for VHA to evaluate the equitable reach, quality, and acceptability of women-focused cancer health services. The BGSoE focuses on providing high-quality and coordinated clinical cancer care. Veterans Health Administration also established the Center for Oncology Outcomes Review and Gender (COURAGE) to evaluate the BGSoE and continue to strengthen cancer care services in VHA. Initial evaluation objectives include establishing an evidence base regarding Veterans with breast and gynecological cancers, including their experiences with cancer care in the VHA. Eventually, COURAGE will provide ongoing monitoring and evaluation to continue to grow and improve cancer care in the VHA.


  • ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure

    by Oyomoare L. Osazuwa-Peters, Melissa A. Greiner, Brystana G. Kaufman, Linda M. Zambrano Guevara, Michaela Dinan, Laura Havrilesky, Haley A. Moss

  • Open Access

    Radical hysterectomy case volume and cervical cancer treatment in the era of COVID-19: A multi-site analysis (2185)

    by Natalie Wickenheisser, Mairead Dillon, Gloria Broadwater, Kathleen Zacherl, Kristin Bixel, Monica Levine, Meredith Newton, Hannah Thel, Katherine Tucker, Paola Gehrig, et al.